MedTrace Logo

ECP for Immune-related Adverse Events After Checkpoint Inhibitor Treatment

NCT05414552 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 11

Last updated 2023-08-01

No results posted yet for this study

Summary

Preliminary data demonstrate that irAEs induced by immune checkpoint blockade can be successfully treated with ECP (Apostolova et al. NEJM 2020). Therefore this retrospective analysis is launched to validate the finding made with the individual patient in a larger patient cohort. The analysis will include the evaluation of safety of ECP treatment in patients with irAEs and collect data on the efficacy of ECP as a treatment for immune-related adverse events and its effect on tumor progression.

Conditions

  • Immune Related Adverse Events
  • Colitis
  • Hepatitis
  • Dermatitis

Interventions

DRUG

ECP

Treatment with ECP for irAEs with 2 cycles performed on two consecutive days, for the first 4 weeks repeated every week, and from week 5 to 12 repeated every two weeks

Sponsors & Collaborators

  • University of Freiburg

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-01
Primary Completion
2022-12-30
Completion
2022-12-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05414552 on ClinicalTrials.gov